Electroacupuncture Reduces Fibromyalgia Pain via Neuronal/Microglial Inactivation and Toll-like Receptor 4 in the Mouse Brain: Precise Interpretation of Chemogenetics.

Fibromyalgia is a chronic pain condition that causes widespread discomfort throughout the body and affects millions of people. Researchers at this study investigated whether electroacupuncture (a form of acupuncture using mild electrical stimulation) could reduce fibromyalgia pain and how it might work in the brain. Using mice with fibromyalgia-like symptoms, scientists compared real electroacupuncture treatment to sham (fake) acupuncture to rule out placebo effects. The mice receiving real electroacupuncture showed significant improvements in both mechanical and thermal pain sensitivity, while those receiving sham treatment did not. The researchers discovered that electroacupuncture works by reducing inflammation in several brain regions including the thalamus, prefrontal cortex, and somatosensory cortex. Specifically, they found that electroacupuncture decreased the activity of a protein called TLR4, which plays a major role in triggering brain inflammation and microglial activation (immune cells in the brain). When TLR4 and related inflammatory molecules were reduced through electroacupuncture treatment, pain levels decreased. This study provides important scientific evidence explaining how electroacupuncture produces pain relief in fibromyalgia beyond just a placebo effect. The findings suggest that electroacupuncture may offer a legitimate treatment option for fibromyalgia patients by targeting specific inflammatory pathways in the brain. While this research was conducted in mice, it opens the door for future human studies and helps validate acupuncture as a therapeutic approach for chronic pain conditions. If considering acupuncture for fibromyalgia, seek treatment from a licensed acupuncturist with experience in pain management.

This preclinical study investigated electroacupuncture's (EA) mechanisms in fibromyalgia using an intermittent cold stress mouse model. Researchers compared EA versus sham EA to control for placebo effects. Fibromyalgia mice demonstrated significant pain hypersensitivity (mechanical threshold: 2.48±0.53g; thermal latency: 5.64±0.32s). EA, but not sham EA, produced significant analgesic effects. Molecular analysis revealed elevated TLR4 expression and inflammatory mediators in the thalamus, medial prefrontal cortex, somatosensory cortex (SSC), and amygdala of FM mice, indicating neuroinflammation and microglial activation. EA treatment significantly downregulated TLR4 and associated inflammatory pathways (MyD88/NF-κB and TRIF/IRF3). Chemogenetic inhibition of SSC activity replicated EA's anti-nociceptive effects via TLR4 pathway modulation. Clinical implications: This study provides mechanistic evidence that EA's analgesic efficacy in fibromyalgia operates through neuroinflammatory pathway modulation, specifically TLR4 signaling downregulation in multiple pain-processing brain regions, supporting EA as a targeted intervention for fibromyalgia management.